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Background: Although a molecular diagnosis is pos-
sible in most patients having Charcot-Marie-Tooth dis-
ease (CMT), recessively inherited and axonal neuropa-
thies still present a diagnostic challenge.
Objective: To determine the cause of axonal CMT type
2 in 3 siblings.
Design: Case report.
Setting: Academic research.
Participants: Three siblings who subsequently devel-
oped profound cerebellar ataxia.
Main Outcome Measures: Muscle biopsy specimen
molecular genetic analysis of thePOLG1 (polymerase-1)
gene, as well as screening of control subjects for POLG1
sequence variants.
Results:Cytochrome c oxidase deficient fibers andmul-
tiple deletions of mitochondrial DNA were detected in
skeletal muscle. Three compound heterozygous substi-
tutions were detected in POLG1.
Conclusion: Even in the absence of classic features of
mitochondrial disease, POLG1 should be considered in
patients having axonal CMT that may be associated with
tremor or ataxia.
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T HE PAST DECADE HAS SEENmajor advances in our un-derstanding of the causes ofinherited neuropathies.Du-plication of the PMP22 (pe-
ripheralmyelin protein 22) gene and point
mutations in GJB1 (gap junction protein,
beta 1) and MPZ (peripheral myelin pro-
tein zero) account for approximately 85%
of unselected cases, but a growing number
of genes have been implicated in the re-
maining 15% of patients, affecting a di-
verse group of cellular processes ranging
from axonal transport to DNA repair.1 The
central role of mitochondria in maintain-
ing peripheral nerve integrity is an emerg-
ing theme, as illustrated by pathogenicmu-
tations inMFN2 (mitofusin 2) and DNM2
(dynamin 2) that disrupt organelle fusion
and fission.1 Although axonal neuropa-
thies are well recognized in patients hav-
ing classic multisystemmitochondrial dis-
ease, isolated neuropathy is uncommon.2
Herein,wedescribe a familymanifesting an
autosomal recessive axonal sensorimotor
neuropathy that dominated the clinical phe-
notype for more than 2 decades. This was
due to compound heterozygousmutations
in the POLG1 gene, which codes for mito-
chondrial DNA (mtDNA) polymerase .
REPORT OF A CASE
A 35-year-oldman hadmanifested abnor-
mal gait and pes cavus at age 10 years.
When initially seen at age 22 years, his
main symptoms were reduced dexterity
and sensory disturbance affecting his face,
hands, and feet. Findings on physical ex-
amination disclosed that he had marked
bilateral distal weakness andwasting of the
small muscles of the forearms, hands,
calves, and feet. His proximal power was
normal. There was clawing of the toes on
the left foot andminimal tremor of the out-
stretched hands. Joint position and vibra-
tion sensewere lost in the toes of both feet.
Nerve conduction studies revealed an axo-
nal sensorimotor neuropathy consistent
with Charcot-Marie-Tooth disease type 2
(CMT2) (Table). He subsequently devel-
oped progressive, predominantly distal
muscle wasting and a postural tremor at
age 33 years, followed by dysarthria.
Neurological examination at age 35
years (a video is available at http://www
.archneurol.com) disclosed that he had a
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prominent side-to-side (no-no) head tremor, slow sac-
cades with upbeat nystagmus on upgaze, and pendular
nystagmus on right lateral gaze, with a full range of
external ocular movements. His visual fields, acuity,
and fundi were normal, but he had cerebellar dysarthria
and dysphagia. Limb examination revealed a postural
and action tremor, marked distal wasting, dysmetria,
and dysdiadochokinesis. He had predominantly distal
symmetric limb weakness, absent tendon reflexes,
and diminished sensation to all 4 modalities in all
9.9 kb
1 2 3 4BA
Figure 1. Skeletal muscle histochemistry and mitochondrial DNA (mtDNA) analysis in the proband. A, Histochemical demonstration of cytochrome c oxidase
activity in muscle highlighting a cytochrome c oxidase–deficient muscle fiber (asterisk) among fibers with normal enzyme activity. B, Long-range polymerase
chain reaction of skeletal muscle DNA amplifying a 9.9-kilobase (kb) fragment across the major mtDNA arc (nucleotide positions 6249-16215). Lane 1 indicates
DNA size marker; lanes 2 and 3, control muscle; and lane 4, muscle from the proband showing multiple mtDNA deletions.
Table. Peripheral Neurophysiological Findings in the Proband and in His Affected Brother
Variable II-1 at Age 21 y II-2 at Age 34 y
Arm
Right sensory
Median (F2-wrist) Absent Absent
Ulnar (F5-wrist) Absent Absent
Radial (forearm-wrist) NA Absent
Sural (calf-ankle) Absent Absent
Superior peroneal (calf-ankle) NA Absent
Motor
Right median (SE on abductor pollicis brevis) DML, ms 3.2 4.2




F latency, ms NA 31
Right ulnar (SE on abductor digiti minimi) DML, ms 2.6 3.5
CV (wrist–above elbow), m/s 61 64
MAP, mV
Wrist 3.2 Broadened MAP 4.5
Above elbow 2.8 Broadened MAP 4.0
Leg
Right sensory
Common peroneal (SE on extensor digitorum brevis) DML NA Absent
Right posterior tibial (SE on abductor hallucis) DML, mV 6.5 Absent
Motor
Right common peroneal (SE on tibialis anterior) DML, ms N/A 3.4
CV (popliteal fossa–fibular neck), m/s 42 At posterior tibial 56
MAP, mV
Fibular neck NA 1.2
Popliteal fossa NA 1.3
Abbreviations: CV, conduction velocity, DML, distal motor latency; MAP, muscle action potential, NA, not available; SE, stimulating electrode.
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4 limbs. He was unable to walk because of weakness
and ataxia.
Hewas theproduct of anonconsanguineousunion,with
healthy parents aged 63 and 61 years. His 40-year-old
brother (II-2)was also initially diagnosed as havingCMT2
(Table) but had a less severe clinical course. His 42-year-
old sister (II-4) developed similar symptoms at age 9 years,
was diagnosed as havingCMT2 inher early 20s, and is now
unable to walk, with severe ataxia (a video is available at
http://www.archneurol.com). A 41-year-old brother (II-3)
was clinically unaffected. Three half-siblings of the father
(data not shown) remain unaffected.
Results of routine blood tests in the proband were
normal. Cerebrospinal fluid examination results were un-
remarkable, except for an elevated lactate level (21.5
mg/dL [to convert to millimoles per liter, multiply by
0.111]). Brain magnetic resonance imaging, echocardi-
ography, and pure-tone audiometry findings were nor-
mal. Neuropsychometry revealed no major deficits. Re-
sults of genetic testing for chromosome 17 duplication,
PMP22,MPZ, and spinocerebellar ataxia types 1, 2, 3, 6,
and 7 expansions were negative. A nerve biopsy speci-
men revealed epineural fibrosis but no evidence of in-
flammation or amyloid.
RESULTS
Muscle histochemistry findings were consistent with on-
going denervation and reinnervation, with fiber-type
grouping. There was amosaic defect of cytochrome c oxi-
dase affecting 6% of muscle fibers (Figure 1A). Long-
range polymerase chain reaction of skeletal muscle DNA
revealedmultiple deletions ofmtDNA(Figure 1B).POLG1
sequencing revealed the following 3 heterozygous sub-
stitutions in the proband: c.191CT in exon2, c.695GA
in exon 3, and c.2209GC in exon 13. Segregation analy-
sis in the family (Figure 2) showed that the c.191CT
and c.695GA substitutions were in cis and inherited
from the mother and that the c.2209GC substitution
was inherited from the father. The affected brother (II-2)
had the same genotype as that of the proband. The un-
affected brother (II-3) had a wild-type sequence.
The frequency of the POLG1 substitutions was deter-
mined by primer extension and by matrix-assisted laser
C CA AG G G GT T
C N CA A AGG T TT
C N
N
CCA A AG GT T
C C NA AG G G GTT
C CN AAA G G TT T
C CCN AA AG G TT
CC NA AG G G GTT
C CN AAA G G TT T
C CCN AA AG G TT
C C CA AG G G GTT
C CAAA G G G TT T









c.191C>T S64L c.191C>T S64L Wild-type 
Genotype
not known 
c.695G>A R232H c.695G>A R232H Wild-type 
c.2209G>C G737R c.2209G>C G737R Wild-type 
Figure 2. Pedigree showing segregation of POLG1 (polymerase -1) gene mutations. N indicates heterozygous substitution; P, the proband; squares, men;
circles, women; shaded symbols, affected; and open symbols, unaffected.
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desorption ionization–time-of-flight mass spectrometry
(MALDITOF; Sequenom, San Diego, California). The
c.191CT substitution was detected in 90 of 294 con-
trol alleles (30.6% [95% confidence interval, 25.4%-
36.2%]). The c.695GA substitution was not detected
in 282 control alleles (95% confidence interval, 0%-
1.06%). The c.2209GC substitution was detected in 2
of 666 control alleles (0.3% [95% confidence interval,
0.04%-1.08%]).
COMMENT
Mitochondrial DNA codes for 13 essential components of
the respiratory chain that is linked to oxidative phosphory-
lation, theprincipal sourceof adenosine triphosphatewithin
the cell. POLG1 mutations affect the maintenance of
mtDNA, causing deletions, point mutations, and deple-
tion of mtDNA. Secondary mtDNA defects lead to a bio-
chemical defect of the respiratory chain in affected tis-
sues, organ dysfunction, and the clinical phenotype.3
The c.695GA and c.2209GC substitutions are the
likely cause of the autosomal recessive axonal sensori-
motor neuropathy in this family. The c.695GA substi-
tution is predicted to alter the highly conserved argi-
nine 232 to histidine in the exonuclease (proofreading)
domain of polymerase , and the c.2209GC substitu-
tion is predicted to change the highly conserved glycine
737 to arginine in the linker region of polymerase . Both
have previously been described in compound heterozy-
gotes having other POLG1 mutations and having mul-
tiple mtDNA deletions4,5; they did not cause disease in
the heterozygous parents and are uncommon in the gen-
eral population. The c.191CT substitution is pre-
dicted to cause a serine to leucine substitution at posi-
tion 64, but this amino acid is located outside the
functional domain of the protein, is not as conserved
across species, is not positioned close to any reported
pathogenic mutations, and was present in approxi-
mately 30% of control alleles.3 Therefore, this substitu-
tion is unlikely to be directly responsible for the disor-
der in this family, although we cannot exclude the
possibility that the serine to leucine substitution at po-
sition 64 contributes to the phenotype, as has been de-
scribed for other polymerase  substitutions present at
high frequencies in control subjects.4
Axonal neuropathies have been described in patients
having dominant and recessive POLG1mutations,4,6-10 of-
ten causing profound sensory ataxia; however, the neu-
ropathy in each case was associated with additional neu-
rological features, pointing toward a multisystem
mitochondrial disorder. By contrast, in all 3 siblings in
the present family, peripheral neuropathy dominated the
clinical picture for 2 decades. Only later did they de-
velop tremor and ataxia, but without the ophthalmople-
gia or dysphagia that characterizes thewell-describedmi-
tochondrial phenotype of SANDO (sensory ataxic
neuropathy with dysphagia and ophthalmoplegia).11
Therefore, our observations add to the broad pheno-
typic spectrumof POLG1-related disease and suggest that
POLG1 should be sequenced in patients having unex-
plained axonal hereditary neuropathy. Althoughmuscle
biopsymay reveal the presence of cytochrome c oxidase–
negative fibers, this is not universally the case,12 and
POLG1 should be sequenced if there is a strong clinical
suspicion.
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